Compare Five9 Inc (FIVN) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Five9 Inc vs Tempus AI — how do they compare? Five9 Inc trades at $35.55 (market cap $2.63B), while Tempus AI trades at $70.12 (market cap $12.58B). The key difference: Tempus AI is far larger — about 4.8× Five9 Inc's market cap, and Five9 Inc is trading nearer its 52-week high, Tempus AI nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Five9 Inc for 72 Days and Tempus AI for 22 Days on average.
| FIVN | TEM | |
|---|---|---|
Market Cap | $2.63B | $12.58B |
Volume | 1,864,393 | 7,444,569 |
Sector | Technology | Broad Market / Factor |
52-Week High | $38.65 | $99.28 |
52-Week Low | $13.61 | $41.55 |
Typical Hold Time | 72 Days | 22 Days |
Enterprise Value | $2.78B | $13.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Five9 (FIVN) trades at $33.78, up 1.47% with strong analyst support (61% buy ratings) and a $34 consensus target. The stock shows bullish technical momentum above key support at $33, supported by consistent earnings beats and accelerating AI revenue growth (78% YoY in Q2 2026). Revenue reached $1.15B in 2025 with improving profitability (net margin 3.43%), though valuation remains elevated at P/E 49.7.
Outlook remains positive with AI-driven subscription growth and raised guidance, but risks include high valuation sensitivity and insider selling. The stock's proximity to its 52-week high suggests near-term consolidation potential, while fundamental improvement supports long-term upside if execution continues.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite recent weakness. The company reported Q2 2026 revenue growth of 22% year-over-year and beat EPS estimates for three consecutive quarters, though it remains unprofitable with a net income margin of -17.77%. Recent positive developments include FDA clearance for its ECG-MR AI product and expanded data licensing agreements, fueling investor optimism in the healthtech sector.
The investment outlook is cautiously optimistic, driven by strong analyst support (64% buy ratings) and a consensus price target of $72.60, implying modest upside. Key opportunities include accelerating adoption of AI-powered diagnostics and strategic acquisitions, but risks persist from persistent cash burn, insider selling, and intense competition in the precision medicine space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Five9 Inc
Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
